Business Wire

ETA

Share
ITB Berlin 2024: Cairo City Break to Become a New Egypt Travel Trend

Cairo is transforming into a long weekend hotspot with the new City Break initiative, announced H.E. Ahmed Issa, the Minister of Tourism and Antiquities of Egypt at ITB Berlin 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306125956/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Minister Ahmed Issa at press conference, ITB Berlin 2024 (Photo: Business Wire)

Cairo City Break Program and A New Era of Luxury Tourism

The new Cairo City Break program is aimed at transforming the capital into a dynamic, must-visit long weekend destination. The visitors will have the opportunity to explore many tourist and archaeological sites by offering diverse and varied tourist experiences encompassing various historical and cultural places, whether Pharaonic, Coptic, or Islamic.

This will contribute to increasing the number of tourist nights spent in Cairo from an average of three to four days to 12 days.

“There is no other city that can offer visitors monuments from every great civilization starting from 3500 B.C. We are dedicated to turning Cairo into a destination that can be enjoyed over the span of multiple visits or a long weekend,” stated the Minister of Tourism and Antiquities, H.E. Ahmed Issa.

Egypt has also been actively developing emerging destinations and elevating traveler's experience at archaeological sites by introducing new destinations and improved, faster, and environmentally friendly ways of commute to key destinations such as Luxor. For instance, in Q4 2025/Q1 2026 Hurghada and Luxor will be connected by a high-speed train.

A Transformative Reform and Infrastructure Development

Egypt's tourism industry is undergoing a transformative reform towards deregulation, paving the way for new investors, and redefining the relationship between the government and the private sector. In tandem with the reform, Egypt’s strategic deregulation efforts and the allocation of 22% of GDP to infrastructure development over the past seven years are paying off, demonstrating a strong commitment to boosting the country's global tourism reputation. The aim is to double Egypt's hotel capacity to 60,000 rooms within the next five years.

Record-Breaking Tourism Results and Main Travel Trends

Egypt witnessed an extraordinary surge in tourism during 2023, with a record 14.906 million visitors gracing its shores — an exponential increase from the 4.9 million recorded in 2021.

This upward trend is expected to continue in 2024, with a remarkable 8% year-on-year growth in the first 50 days of the year. Most visitors come from Germany, with 1.6 million tourists recorded last year, followed by Russia, Saudi Arabia, Italy, and the United Kingdom.

About the Egyptian Tourism Authority

Established in 1981, the Egyptian Tourism Authority is dedicated to promoting Egypt's vast historical assets and diverse destinations, fostering domestic tourism, and connecting Egyptians with their rich heritage. Under the leadership of the Minister of Tourism, the Egyptian Tourism Authority spearheads marketing strategies, supports tourism development, and sponsors various events to enhance Egypt's tourism industry.

For more information, visit Experience Egypt.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306125956/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye